"We believe that there is significant potential with Nammi's immunocytokine technology in the treatment of multiple cancer ...

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

Those eligible are myeloma patients whose cancer has returned and stopped responding to previous drugs, and who have had ...

(RTTNews) - Johnson & Johnson (JNJ), Friday announced the submission of regulatory applications for Darzalex Faspro to the U.S. Food and Drug Administration, and Darzalex to the European Medicines ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Treatment for myeloma usually involves a type of radiation therapy called external beam radiation therapy. This type uses a machine outside of the body to aim radiation at the cancerous cells.

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Receiving the once-weekly KRd56 treatment ...